D042: Role of prosaposin (PSAP) in liver steatosis-triggered hepatocellular carcinoma
FAU own research funding: EFI / IZKF / EAM ...
Start date : 01.04.2023
End date : 30.09.2025
Project details
Scientific Abstract
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of hepatocellular carcinoma (HCC). Furthermore, NAFLD promotes HCC progression but the mechanism are elusive. Our preliminary work indicates that enhanced expression of prosaposin (PSAP) in NAFLD promotes HCC growth. Therefore, this project aims to characterize the molecular mechanisms by which PSAP affects HCC cells, to test the therapeutic potential of PSAP inhibition and to validate the function of PSAP in clinical HCC samples.
Involved:
Claus Hellerbrand
Project Leader
Melanie Kappelmann-Fenzl
Project Member
Martin Fromm
Project Member
Peter Dietrich
Project Member
Contributing FAU Organisations:
Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie
Interdisziplinäres Zentrum für Klinische Forschung (IZKF)
Lehrstuhl für Biochemie und Molekulare Medizin
Professur für Biochemie und Molekulare Pathobiologie
Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology
Medizinische Fakultät
